These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
890 related articles for article (PubMed ID: 15383187)
21. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077 [TBL] [Abstract][Full Text] [Related]
24. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Ferrer-GarcĂa JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754 [TBL] [Abstract][Full Text] [Related]
26. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Farsang C; Athyros V; Gaw A; Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Leibovitz E; Harats D; Gavish D Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
29. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
31. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP; Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014 [TBL] [Abstract][Full Text] [Related]
32. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708 [TBL] [Abstract][Full Text] [Related]
33. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668 [TBL] [Abstract][Full Text] [Related]
34. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Dorval JF; Anderson T; Buithieu J; Chan S; Hutchison S; Huynh T; Jobin J; Lonn E; Poirier P; Title L; Walling A; Tran T; Boudreau G; Charbonneau F; Genest J Am J Cardiol; 2005 Jan; 95(2):249-53. PubMed ID: 15642561 [TBL] [Abstract][Full Text] [Related]
35. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926 [TBL] [Abstract][Full Text] [Related]
36. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620 [TBL] [Abstract][Full Text] [Related]
37. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079 [TBL] [Abstract][Full Text] [Related]
38. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Milionis HJ; Rizos E; Kostapanos M; Filippatos TD; Gazi IF; Ganotakis ES; Goudevenos J; Mikhailidis DP; Elisaf MS Curr Med Res Opin; 2006 Jun; 22(6):1123-31. PubMed ID: 16846545 [TBL] [Abstract][Full Text] [Related]
39. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kuryata OV; Yegorova YV Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]